Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,106.14 -10.03 (-0.20%) Dow
38,212.22 -173.87 (-0.45%) Nasdaq
15,939.57 -43.51 (-0.27%) Bitcoin USD
62,955.66 -677.18 (-1.06%) CMC Crypto 200
1,306.17 -32.89 (-2.46%)
COMPASS Pathways plc (CMPS)
| Previous close | 8.11 |
| Open | 7.99 |
| Bid | 7.91 x 100 |
| Ask | 8.14 x 100 |
| Day's range | 7.89 - 8.05 |
| 52-week range | 5.01 - 12.75 |
| Volume | |
| Avg. volume | 677,175 |
| Market cap | 550.157M |
| Beta (5Y monthly) | 2.48 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression
LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Journey Clinical, a leading psychedelic-assisted psychotherapy platform with the largest network of licensed therapists focused on psychedelics in the US, today announced they have entered into a research collaboration agreement to inform the development of a scalable and practical delivery
- GlobeNewswire
Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference
LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the 23rd Annual Needham Virtual Healthcare Conference at 8:00am ET on April 9, 2024. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible
- GlobeNewswire
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New ChairLONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that Board Chair and co-founder George Goldsmith and fellow co-founder Ekaterina Malievskaia have resigned their seats on the company’s board of directors, effective March 29, 2
